Exploring the potential role of neuromodulatory drugs in radical prostatectomy patients

Journal of Andrology

Volumn 30, Issue 4, 2009, Pages 377-383

  Mulhall, John P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cavernous nerve; Erectile function; Immunophilin ligand; Neuromodulation; Neuropraxia

Indexed keywords

IMMUNOPHILIN; TACROLIMUS;

CONFERENCE PAPER; ELECTROSTIMULATION; ERECTILE DYSFUNCTION; HUMAN; NERVE INJURY; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PELVIS SURGERY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURGICAL TECHNIQUE;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERYTHROPOIETIN; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PENILE ERECTION; PENIS; PIPERAZINES; PROSTATECTOMY; PURINES; RATS; SULFONES;

EID: 68549096139     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.108.006866     Document Type: Conference Paper

References (45)

1. Allaf ME, Hoke A, Burnett AL. Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol. 2005;174:2060-2064. (Pubitemid 41547024)
2. Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346:1138-1144.
3. Bella AJ, Hayashi N, Carrion RE, Price R, Lue TF. FK1706 enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat. J Sex Med. 2007;4:341-346; discussion 346-347. (Pubitemid 46394708)
4. Burgers JK, Nelson RJ, Quinlan DM, Walsh PC. Nerve growth factor, nerve grafts and amniotic membrane grafts restore erectile function in rats. J Urol. 1991;146(2)463-468.
5. Burnett AL. Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy. Urology. 2003;61:491-497.
6. Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury. J Urol. 2004;171:495-500.
7. Burnett AL, Teloken PE, Briganti A, Whitehurst T, Montorsi F. Intraoperative assessment of an implantable electrode array for cavernous nerve stimulation. J Sex Med. 2008;5:1949-1954.
8. Campana W, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J. 2001;15:1804-1806.
9. Carrier S, Zvara P, Nunes L, Kour NW, Rehman J, Lue TF. Regeneration of nitric oxide synthase-containing nerves after cavernous nerve neurotomy in the rat. J Urol. 1995;153:1722-1727.
10. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999;162:433-438.
11. Celik M, Gökmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A. 2002;99:2258-2263. (Pubitemid 34169048)
12. Chunasuwankul R, Ayrout C, Dereli Z, Gal A, Lanzetta M, Owen E. Low dose discontinued FK506 treatment enhances peripheral nerve regeneration. Int Surg. 2002;87:274-278.
13. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505. (Pubitemid 36337492)
14. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The national Medicare experience: 1988-1990 (updated June 1993). Urology. 1993;42:622-629.
15. Gold BG, Katoh K, Storm-Dickerson T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci. 1995;11:7509-7516.
16. Gold BG, Storm-Dickerson T, Austin DR. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. Restor Neurol Neurosci. 1994;6:287-296. (Pubitemid 24184243)
17. Jonler M, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of radical prostatectomy. Br J Urol. 1994;74:352-358.
18. Junemann KP, Persson-Junemann C, Lue TF, Tanagho EA, Alken P. Neurophysiological aspects of penile erection: the role of the sympathetic nervous system. Br J Urol. 1989a;64:84-92. (Pubitemid 19177149)
19. Junemann KP, Persson-Junemann C, Tanagho EA, Alken P. Neurophysiology of penile erection. Urol Res. 1989b;17:213-217.
20. Khan Z, Ferrari G, Kasper M, Tonge DA, Steiner JP, Hamilton GS, Gordon-Weeks PR. The non-immunosuppressive immunophilin ligand GPI-1046 potently stimulates regenerating axon growth from adult mouse dorsal root ganglia cultured in Matrigel. Neuroscience. 2002;114:601-609. (Pubitemid 35247648)
21. Leandri P, Rossignol G, Gautier JR, Roman J. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol. 1992;147:883-887.
22. Leungwattanakij S, Bivalacqua TJ, Usta MF, Yang DY, Hyun JS, Champion HC, Abdel-Mageed AB, Hellstrom WJ. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003;24:239-245.
23. Liu T, Allaf ME, Lagoda G, Burnett AL. Erythropoietin receptor expression in the human urogenital tract: immunolocalization in the prostate, neurovascular bundle and penis. BJU Int. 2007;100:1103-1106. (Pubitemid 47537674)
24. Lue TF, Gleason CA, Brock GB, Carroll PR, Tanagho EA. Intraoperative electrostimulation of the cavernous nerve: technique, results and limitations. J Urol. 1995;154:1426-1428.
25. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll PR. Predictors of treatment after initial surveillance in men with cancer of the prostate: results from CaPSURE. J Urol. 2003;170:2279-2283. (Pubitemid 37413975)
26. Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, Stief C. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;54:924-931.
27. Mulhall JP. Does on-demand vardenafil improve erectile function recovery after radical prostatectomy? Nat Clin Pract. 2009;6:14-15.
28. Mulhall JP, Muller A, Donohue JF, Golijanin D, Tal R, Akin-Olugbade Y, Kobylarz K, Cohen-Gould L, Bennett NE, Scardino P. FK506 and erectile function preservation in the cavernous nerve injury model: optimal dosing and timing. J Sex Med. 2008. (Pubitemid 351337882)
29. Mulhall JP, Muller A, Donohue JF, Mullerad M, Kobylarz K, Paduch DA, Tal R, Li PS, Cohen-Gould L, Scardino PT. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med. 2008. (Pubitemid 351606701)
30. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, Giuliano F, Brock G. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res. 2008;20:479-486.
31. Quinlan DM, Nelson RJ, Partin AW, Mostwin JL, Walsh PC. The rat as a model for the study of penile erection. J Urol. 1989;141:656-661. (Pubitemid 19089182)
32. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164:1929-1934. (Pubitemid 30835426)
33. Raina R, Pahlajani G, Agarwal A, Zippe CD. Early penile rehabilitation following radical prostatectomy: Cleveland clinic experience. Int J Impot Res. 2008;20:121-126.
34. Schreiber SL, Crabtree GR. Immunophilins, ligands and the control of signal transduction. Harvey Lect. 1997;91:99-114.
35. Sezen SF, Blackshaw S, Steiner JP, Burnett AL. FK506 binding protein 12 is expressed in rat penile innervation and upregulated after cavernous nerve injury. Int J Impot Res. 2002;14:506-511. (Pubitemid 36068430)
36. Sezen SF, Hoke A, Burnett AL, Snyder SH. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med. 2001;7:1073-1075. (Pubitemid 33009995)
37. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature. 1994;371:336-339. (Pubitemid 24300615)
38. Siegel T, Moul JW, Spevak M, Alvord WG, Costabile RA. The development of erectile dysfunction in men treated for prostate cancer. J Urol. 2001;165:430-435. (Pubitemid 32060430)
39. Snyder SH, Sabatini DM, Lai MM, Steiner JP, Hamilton GS, Suzdak PD. Neural actions of immunophilin ligands. Trends Pharmacol Sci. 1998;19:21-26.
40. Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998;16:275-283. (Pubitemid 28041609)
41. User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol. 2003; 169:1175-1179.
42. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982;128:492-497.
43. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology. 2000;55:58-61. (Pubitemid 30050758)
44. Walsh PC, Partin AW, Epstein JL. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol. 1994;152:1831-1836. (Pubitemid 24322640)
45. Zippe CD, Kedia AW, Kedia K, Nelson DR, Agarwal A. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology. 1998;52:963-966. (Pubitemid 28533359)